Literature DB >> 21809376

Unique angiogenic and vasculogenic properties of renal cell carcinoma in a xenograft model of bone metastasis are associated with high levels of vegf-a and decreased ang-1 expression.

Chao Xie1, Edward M Schwarz, Erik R Sampson, Robinder S Dhillon, Dan Li, Regis J O'Keefe, Wakenda Tyler.   

Abstract

Management of various tumor metastases to bone has dramatically improved, but this is not so for renal cell carcinoma (RCC), which is a difficult surgical problem due to its great vascularity. Furthermore, the unique mechanisms that mediate RCC vasculogenesis in bone remain unknown. To understand this process we developed a xenograft model that recapitulates highly vascular RCC versus less vascular tumors that metastasize to bone. Human tumor cell lines of RCC (786-O), prostate cancer (PC3), lung cancer (A549), breast cancer (MDA-MB231), and melanoma (A375) were transduced with firefly luciferase (Luc), injected into the tibiae of nude mice, and differences in growth, osteolysis, and vascularity were assessed by longitudinal bioluminescent imaging, micro-CT for measurement of calcified tissues and vascularity and histology. The results showed that while RCC-Luc has reduced growth and osteolytic potential versus the other tumor lines, it displayed a significant increase in vascular volume (p < 0.05). This expansion was due to 3- and 5-fold increases in small and large vessel numbers respectively. In vitro gene expression profiling revealed that RCC-Luc expresses significantly (p < 0.05) more vegf-a (10-fold) and 20- to 30-fold less ang-1 versus the other lines. These data demonstrate the utility of this model to study the unique vasculogenic properties of RCC bone metastases.
Copyright © 2011 Orthopaedic Research Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21809376      PMCID: PMC3213285          DOI: 10.1002/jor.21500

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  43 in total

1.  Leaky vessels? Call Ang1!

Authors:  R K Jain; L L Munn
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  Angiopoietin-1 protects the adult vasculature against plasma leakage.

Authors:  G Thurston; J S Rudge; E Ioffe; H Zhou; L Ross; S D Croll; N Glazer; J Holash; D M McDonald; G D Yancopoulos
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

3.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1.

Authors:  G Thurston; C Suri; K Smith; J McClain; T N Sato; G D Yancopoulos; D M McDonald
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

Review 4.  Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.

Authors:  Alain Ravaud
Journal:  Oncologist       Date:  2011

5.  Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.

Authors:  T Kamura; S Sato; K Iwai; M Czyzyk-Krzeska; R C Conaway; J W Conaway
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

6.  The natural history of noncastrate metastatic prostate cancer after radical prostatectomy.

Authors:  Ofer Yossepowitch; Fernando J Bianco; Scott E Eggener; James A Eastham; Howard I Scher; Peter T Scardino
Journal:  Eur Urol       Date:  2006-10-30       Impact factor: 20.096

7.  Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.

Authors:  Roy S Herbst; David Hong; Linnea Chap; Razelle Kurzrock; Edward Jackson; Jeffrey M Silverman; Erik Rasmussen; Yu-Nien Sun; Don Zhong; Yuying C Hwang; Jeffrey L Evelhoch; Jonathan D Oliner; Ngocdiep Le; Lee S Rosen
Journal:  J Clin Oncol       Date:  2009-06-22       Impact factor: 44.544

8.  Expression and function of angiopoietin-1 in breast cancer.

Authors:  A J Hayes; W Q Huang; J Yu; P C Maisonpierre; A Liu; F G Kern; M E Lippman; S W McLeskey; L Y Li
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

9.  Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state.

Authors:  J J Haigh; H P Gerber; N Ferrara; E F Wagner
Journal:  Development       Date:  2000-04       Impact factor: 6.868

Review 10.  Tumor metastasis to bone.

Authors:  Mandeep S Virk; Jay R Lieberman
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more
  8 in total

1.  Three-dimensional (3D) culture of bone-derived human 786-O renal cell carcinoma retains relevant clinical characteristics of bone metastases.

Authors:  Tianhong Pan; Eliza L S Fong; Mariane Martinez; Daniel A Harrington; Sue-Hwa Lin; Mary C Farach-Carson; Robert L Satcher
Journal:  Cancer Lett       Date:  2015-05-21       Impact factor: 8.679

2.  Efficacy of Bisphosphonate-Conjugated Sitafloxacin in a Murine Model of S. aureus Osteomyelitis: Evidence of "Target & Release" Kinetics and Killing of Bacteria Within Canaliculi.

Authors:  Youliang Ren; Thomas Xue; Joshua Rainbolt; Karen L de Mesy Bentley; Chad A Galloway; Yuting Liu; Philip Cherian; Jeffrey Neighbors; Marloes I Hofstee; Frank H Ebetino; Thomas Fintan Moriarty; Shuting Sun; Edward M Schwarz; Chao Xie
Journal:  Front Cell Infect Microbiol       Date:  2022-06-24       Impact factor: 6.073

Review 3.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

4.  Increased Insulin mRNA Binding Protein-3 Expression Correlates with Vascular Enhancement of Renal Cell Carcinoma by Intravenous Contrast-CT and is Associated with Bone Metastasis.

Authors:  Chao Xie; Yaying Li; Qingqing Li; Yu Chen; Jorge Yao; Guoyong Yin; Qing Bi; Regis J O'Keefe; Edward M Schwarz; Wakenda Tyler
Journal:  J Bone Oncol       Date:  2015-09-12       Impact factor: 4.072

Review 5.  Choosing the right cell line for renal cell cancer research.

Authors:  Klaudia K Brodaczewska; Cezary Szczylik; Michal Fiedorowicz; Camillo Porta; Anna M Czarnecka
Journal:  Mol Cancer       Date:  2016-12-19       Impact factor: 27.401

6.  Exploration of an Integrative Prognostic Model of Radiogenomics Features With Underlying Gene Expression Patterns in Clear Cell Renal Cell Carcinoma.

Authors:  Yeqian Huang; Hao Zeng; Linyan Chen; Yuling Luo; Xuelei Ma; Ye Zhao
Journal:  Front Oncol       Date:  2021-03-08       Impact factor: 6.244

Review 7.  Urological cancer organoids, patients' avatars for precision medicine: past, present and future.

Authors:  Haotian Chen; Wentao Zhang; Niraj Maskey; Fuhan Yang; Zongtai Zheng; Cheng Li; Ruiliang Wang; Pengfei Wu; Shiyu Mao; Junfeng Zhang; Yang Yan; Wei Li; Xudong Yao
Journal:  Cell Biosci       Date:  2022-08-19       Impact factor: 9.584

8.  Cadherin-11 in renal cell carcinoma bone metastasis.

Authors:  Robert L Satcher; Tianhong Pan; Chien-Jui Cheng; Yu-Chen Lee; Song-Chang Lin; Guoyu Yu; Xiaoxia Li; Anh G Hoang; Pheroze Tamboli; Eric Jonasch; Gary E Gallick; Sue-Hwa Lin
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.